skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost

Original Research

(1520) Views  (543) Full article downloads

Authors: E Randy Craven, Ching-Chi Liu, Amy Batoosingh, et al

Published Date December 2010 Volume 2010:4 Pages 1433 - 1440
DOI: http://dx.doi.org/10.2147/OPTH.S14915

E Randy Craven1, Ching-Chi Liu2, Amy Batoosingh2, Rhett M Schiffman2, Scott M Whitcup2
1Glaucoma Consultants of Colorado, Denver, CO, USA; 2Allergan, Inc., Irvine, CA, USA; This work was presented in part at the 19th Annual Meeting of the American Glaucoma Society (AGS); March 5–8, 2009; San Diego, CA, USA

Purpose: To evaluate conjunctival hyperemia associated with bimatoprost 0.01% treatment in patients who replace latanoprost 0.005% with bimatoprost 0.01%.
Methods: Randomized, double-masked, vehicle-controlled, multicenter study of patients with ocular hypertension or glaucoma whose intraocular pressure (IOP) was adequately controlled on latanoprost monotherapy. At baseline, patients discontinued latanoprost and were randomized to treatment with once-daily bimatoprost 0.01% (n = 151) or vehicle (n = 71). The primary endpoint was the peak change in macroscopic hyperemia (conjunctival hyperemia evaluated by gross visual inspection) from baseline to month 1.
Results: Bimatoprost 0.01% was noninferior to vehicle in the mean [standard deviation] peak change from baseline macroscopic hyperemia at month 1 (0.18 [0.46] in the bimatoprost 0.01% group vs 0.02 [0.32] in the vehicle group, P = 0.009). The between-group difference was 0.15 (95% confidence interval [CI]: 0.04, 0.26), which was within the predefined margin for noninferiority of 0.5 on a hyperemia grading scale of 0 to +3. There were no statistically significant between-group differences in the percentage of patients with a ≥1-grade increase in macroscopic hyperemia from baseline. Mean IOP was decreased from baseline (-0.7 to -1.3 mm Hg) in the bimatoprost 0.01% group (P ≤ 0.002) and was increased from baseline (+3.3 to +3.6 mm Hg) in the vehicle group (P < 0.001) at month 1. There were no statistically significant between-group differences in adverse events.
Conclusions: Bimatoprost 0.01% was noninferior to vehicle with respect to conjunctival hyperemia in this study population. Replacement of latanoprost with bimatoprost 0.01% in patients with ocular hypertension or glaucoma can result in additional IOP reduction without clinically important hyperemia.

Keywords: conjunctiva, glaucoma, hyperemia, intraocular pressure, prostaglandin analogs, topical drug administration






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
Eye disorders in patients with multiple sclerosis: natural history and management
Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects